Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/2003
11/27/2003US20030220351 Enteric coating made of methacrylic acid copolymer; system may also include a subcoating; resists disintegration and release of caffeine at pH less than 5, but disintegrates rapidly to release caffeine at pH greater than 6
11/27/2003US20030220348 Substituted imidazolylmethyl pyridine and pyrazine deriviatives GABAa receptor ligands
11/27/2003US20030220339 Heterocyclic arylsulfonamidobenzylic compounds
11/27/2003US20030220338 Fungal efflux pump inhibitors
11/27/2003US20030220330 Anilinopyrimidine derivatives as JNK pathway inhibitors and compositions and methods related thereto
11/27/2003US20030220312 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of cardiovascular disorders
11/27/2003US20030220310 For treatment of circulatory disorders, cardiovascular disorders (hypertension), cirrhosis and ascites
11/27/2003US20030220308 Comprises lumisterol and tachysterol, for topical administration
11/27/2003US20030220306 Transcripts harboring inton 1, or fragment thereof; preventing or treating Alzheimer's Disease; ameliorating a neurodegenerative condition; modulating amyloid precursor protein; selectively inhibiting COX-3 or PCOX-1a activity
11/27/2003US20030220299 Use of substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds for treating hepatitis virus infections
11/27/2003US20030220297 Phosphorus-containing compounds and uses thereof
11/27/2003US20030220293 Having high dissolution profile and in vivo enhanced bioavailability
11/27/2003US20030220292 Treatment of erectile dysfunction
11/27/2003US20030220291 Compounds for the treatment of psychiatric or substance abuse disorders
11/27/2003US20030220281 To inhibit the activity of elastase or cathepsin G, thereby inhibiting ectopic implantation of endometrial fragments.
11/27/2003US20030220280 Schwann cell bridge implants and phosphodiesterase inhibitors to stimulate CNS nerve regeneration
11/27/2003US20030220266 Administering an inhibitor of cyclooxygenase-1 and/or an EP2 and/or EP4 receptor antagonist to treat cervical cancer
11/27/2003US20030220255 GLP-1 agonist and cardiovascular complications
11/27/2003US20030220241 Method of treating cancer
11/27/2003US20030220232 Peptide with the sequence Gln-Tyr-Asn-Ala-Asp and derivatives differing from the original sequence by the addition, substitution, inversion, insertin, deletion or modification of one or more amino acids; sodium ion channel binder
11/27/2003US20030220228 Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions and methods of use
11/27/2003US20030220226 Compounds and compositions for delivering active agents
11/27/2003US20030219887 Crystals of glucokinase and methods of growing them
11/27/2003US20030219874 Comprises endothelial differentiation gene receptor proteins (EDG8) for monitoring receptivity to and/or diagnosing cancer, angiogenesis and inflammation
11/27/2003US20030219860 Comprises nucleotide sequences coding novel tumor necrosis factor receptor (TRAIN-R) for treating inflammatory bowel disease and arthritic condition; antiinflammatory agents
11/27/2003US20030219768 Lung cancer therapeutics and diagnostics
11/27/2003US20030219739 Comprises muscle protein for treating and preventing of muscle atrophy
11/27/2003US20030219500 Drink for athletes; creatine plays a pivotal role in the regulation and homeostasis of skeletal muscle energy metabolism
11/27/2003US20030219495 To prevent or reverse hypotension, unstable angina, myocardial infarction or shock caused by the concomitant ingestion of a phosphodiesterase inhibitor such as sildenafil citrate and a NO-donor such as L-arginine or an organic nitrate
11/27/2003US20030219494 Compositions and methods of using them
11/27/2003US20030219490 Nanoparticulate megestrol formulations
11/27/2003US20030219488 Sustained-release formulation of a cyclooxygenase-2 inhibitor
11/27/2003US20030219476 Administering to a mammal a pharmaceutical formulation containing mitoxantrone in a cardiolipin (a liposome), and a excipient to treat cancer and multiple sclerosis
11/27/2003US20030219472 Compositions and method for transmucosal drug delivery and cryoprotection
11/27/2003US20030219465 Composition for delivery of dithranol
11/27/2003US20030219461 Treating inflammation by administering antibiotics (penicillin) and cyclooxygenase-2 inhibitor (celecoxib)
11/27/2003US20030219437 Administering antibodies used as antagonists to CD antigen ligands on the cells, for prophylaxis of cardiovascular, gastrointestinal or urogenital disorders
11/27/2003US20030219419 Alteration of cell membrane for new functions
11/27/2003US20030219411 Modulators of the function of FAS receptors and other proteins
11/27/2003US20030219403 Compositions and methods of tolerizing a primate to an antigen
11/27/2003US20030219401 Combination of an aldosterone receptor antagonist and a bile acid sequestering agent
11/27/2003US20030219400 Methods for treating or inhibiting neurotoxin-mediated syndromes
11/27/2003US20030219392 Composition to enhance permeation of topical skin agents
11/27/2003US20030219382 Cancer-linked gene as target for chemotherapy
11/27/2003US20030219379 Antiproliferative agent
11/27/2003US20030219377 Brain disorders; Alzheimer's disease
11/27/2003US20030219354 Deactivation pathogens; using riboflavin sensitizers; exposure to light source
11/27/2003CA2830619A1 Glucan-based vaccines
11/27/2003CA2794297A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione or 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of amyloidosis
11/27/2003CA2794060A1 Methods and compositions using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione for treatment and management of multiple myeloma
11/27/2003CA2752140A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
11/27/2003CA2752127A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of hepatocellular carcinoma
11/27/2003CA2752124A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of head and neck cancer
11/27/2003CA2752122A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of ovarian cancer
11/27/2003CA2727830A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of multiple myeloma
11/27/2003CA2727824A1 Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment and management of solid tumors
11/27/2003CA2511604A1 Treatment of cancer by the use of anti fas antibody
11/27/2003CA2497601A1 Pyrroloquinoline quinone for treatment of cardiac injury and methods of use thereof
11/27/2003CA2486881A1 Process for the preparation and activation of substances and a means of producing same
11/27/2003CA2486583A1 Marker molecules associated with lung tumors
11/27/2003CA2486327A1 Htlv-i tax induced killing of p53 null cancer cells
11/27/2003CA2486302A1 Methods for the prevention and/or the treatment of neurological disorders
11/27/2003CA2486141A1 Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
11/27/2003CA2486121A1 Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
11/27/2003CA2486028A1 Method of identifying pancreatic ductal carcinoma-specific gene using pancreatic ductal cells, method of testing for pancreatic ductal carcinoma using pancreatic ductal carcinoma-specific gene that is identified by the method, and method of screening pharmaceutical candidate compound for treating or preventing pancreatic ductal carcinoma
11/27/2003CA2486000A1 Use of compounds that are effective as selective opiate receptor modulators
11/27/2003CA2485847A1 Glucan-based vaccines
11/27/2003CA2485465A1 Methods of treating hepatitis
11/27/2003CA2485399A1 Co-grinding process for the preparation of a ternary composition
11/27/2003CA2485081A1 Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
11/27/2003CA2484989A1 Methods and compositions for treating t cell mediated inflammatory/autoimmune diseases and disorders in subjects having a glucocorticoid regulation deficiency
11/27/2003CA2484702A1 Substituted 4-aryl-4h-pyrrolo[2,3-h]chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
11/27/2003CA2484671A1 Cyanoguanidine prodrugs
11/27/2003CA2484654A1 A selective inos inhibitor and a pde inhibitor in combination for the treatment of respiratory diseases
11/27/2003CA2484324A1 Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
11/27/2003CA2482746A1 Combination of a beta-2 adrenoceptor agonists and an aminosugars and their use for the treatment immunomodulatory disorders
11/27/2003CA2482348A1 Combinations of an ace inhibitor, a calcium channel blocker and a diuretic
11/26/2003EP1365246A1 Diagnostics and therapeutics for diseases associated with neuromedin U2 receptor (NMU2)
11/26/2003EP1365034A2 Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasia
11/26/2003EP1365032A1 Marker molecules associated with lung tumors
11/26/2003EP1364962A1 Use of monocarboxylate transporter proteins for thyroid hormone transport
11/26/2003EP1364659A1 Remedies for urinary diseases comprising lpa receptor controlling agents
11/26/2003EP1364652A1 Remedies for lung cancer
11/26/2003EP1364649A1 Adduct of topiramate and tramadol hydrochioride and uses thereof
11/26/2003EP1364642A1 Composition for delivery of dithranol
11/26/2003EP1364628A1 Coated medical devices
11/26/2003EP1364069A1 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
11/26/2003EP1364051A2 Screening methods to identify compounds that modulate a response of a cell to ultraviolet radiation exposure
11/26/2003EP1364019A2 Methods and compositions relating to muscle specific sarcomeric calcineurin-binding proteins (calsarcins)
11/26/2003EP1364018A2 Isolated human nuclear hormone receptors, nucleic acid molecules encoding human nuclear hormone receptors, and uses thereof
11/26/2003EP1363996A2 Epothilone resistant cell lines
11/26/2003EP1363994A2 Thymic epithelial progenitor cells and uses thereof
11/26/2003EP1363993A2 METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF I$g(k)B KINASE (IKK)
11/26/2003EP1363950A2 Bispecific monoclonal antibodies to il-12 and il-18 receptors
11/26/2003EP1363920A1 Modified psma ligands and uses related thereto
11/26/2003EP1363914A1 Aryl substituted alkylcarboxylic acids as hypocholesterolemic agents
11/26/2003EP1363913A2 Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose
11/26/2003EP1363897A2 Antagonists of mcp-1 function and methods of use thereof
11/26/2003EP1363876A1 Glucocorticoid receptor modulators
11/26/2003EP1363705A1 Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
1 ... 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 ... 1151